GFS
VRTX icon

GYL Financial Synergies’s Vertex Pharmaceuticals VRTX Stock Holding History

GYL Financial Synergies’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$6.92M Sell
14,882
-276
-2% -$133K 0.52% 49
2024
Q2 		$7.1M Buy
15,158
+30
+0.2% +$13K 0.55% 45
2024
Q1 		$6.32M Sell
15,128
-95
-0.6% -$40.2K 0.5% 52
2023
Q4 		$6.19M Buy
15,223
+272
+2% +$100K 0.51% 49
2023
Q3 		$5.2M Buy
14,951
+406
+3% +$142K 0.51% 49
2023
Q2 		$5.12M Buy
+14,545
New +$4.9M 0.47% 53

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

GYL Financial Synergies's VRTX Position: Q3 2024 in Review

GYL Financial Synergies reduced its Vertex Pharmaceuticals (VRTX) stake by 1.8% in Q3 2024, selling an estimated $133K and leaving 14,882 shares worth $6.92M. The position accounts for 0.52% of the portfolio, ranked #49.

GYL Financial Synergies first reported a position in VRTX in Q2 2023 and has held it in 6 quarters since. The position peaked at $7.1M in Q2 2024. 1,547 funds tracked by Wall St. Rank hold VRTX as of Q3 2024.

  • GYL Financial Synergies held 14,882 shares of Vertex Pharmaceuticals worth $6.92M as of Q3 2024.
  • GYL Financial Synergies sold 276 Vertex Pharmaceuticals shares in Q3 2024, an estimated $133K.
  • Vertex Pharmaceuticals made up 0.52% of GYL Financial Synergies's portfolio in Q3 2024, its #49 holding.
  • GYL Financial Synergies first reported a position in Vertex Pharmaceuticals in Q2 2023 and has held it in 6 quarters since.
  • GYL Financial Synergies's Vertex Pharmaceuticals position peaked at $7.1M in Q2 2024.
  • 1,547 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2024.

Based on GYL Financial Synergies's 13F filing for Q3 2024, filed 7 Nov 2024.